ISPE 2026
August 29–September 2, 2026 | Milan, Italy
Gold Sponsor
August 2026
Carelon Research is a proud sponsor of ISPE 2026. Visit us in person at booth #408. Connect with our experts and see our latest research.
SKILLS COURSE
Saturday, August 29, 2026, 2:30–6:00 p.m. CEST
Location: Amber 1+2, Level 2
[SC-14] Using pharmacoepidemiology database resources to address drug safety research
Course Leader:
Daniel C. Beachler, PhD, MHS, FISPE
Staff Vice President, Safety and Epidemiology, Carelon Research, USA
Carelon Research presentations
Carelon Research authors are indicated in bold.
|
Podium presentations |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Monday, August 31, 2026 |
1F-Three Panels on Methods (mini session: Know Your Data & Validate) |
Know Your Data & Validate |
Beachler DC[1], Gini R[2] (Co-moderators) |
[1] Carelon Research, USA, [2] ARS Toscana, Italy |
|
Monday, August 31, 2026 |
2C-How Do Exposed Pregnancies End? |
Pregnancy Outcomes after Pfizer-BioNTech Monovalent COVID-19 Vaccination during Pregnancy in the United States |
Shinde MU[1], Kawai AT[2], Cosgrove A[1], Koram N[3], Hawrusik R[1], Rajbhandari R[1], Kempner ME[1], Avula R[4], Barrett K[1], Daniels K[4], DeFor T[5], DeVries A[6], Diessner BJ[7], Djibo DA[8], Ezzy SM[7], Cai B[3], Layton JB[2], Mayer SE[9], Messenger-Jones E[1], Michaelidis M[1], Love SAM[4], Ma Q[6], Nolan MB[5], Selvan M[6], Taggert E[7], McMahill-Walraven CN[10], Wang X[8], Wideman K[2], Ziyadeh NJ[7], Platt R[11], Bell EJ[1], Fuller CC[9], Gilsenan AW[2] |
[1] Harvard Pilgrim Health Care Institute, USA, [2] RTI Health Solutions, USA, [3] Pfizer, Inc., USA, [4] Carelon Research, USA, [5] HealthPartners Institute, USA, [6] Humana Healthcare Research, Inc., USA, [7] Optum, USA, [8] CVS Health, USA, [9] Harvard Medical School and Harvard Pilgrim Health Care Institute, USA, [10] Glade Oak Inc., USA, [11] Harvard Medical School, USA |
|
Monday, August 31, 2026 From our parent company, Elevance Health |
2B - Being methodologic in drug utilization: Navigating Definitions, Patterns, and Real-World Challenges |
Data-Driven Outreach Prioritization for Pharmacy Home Delivery Adoption Among Medicare Population |
Yin R[1], Li Y[1], Reminjuse C[1], Scott J[1] |
[1] Elevance Health, USA |
|
Tuesday, September 1, 2026 |
3F-Three Panels on Safety & Effectiveness (mini session: Safety of COVID-19 Vaccines: the Final Answer) |
Risk of Myocarditis/Pericarditis After Receipt of Pfizer-BioNTech COVID-19 Vaccine: Results from a Post-approval Safety Study in the US |
Kawai AT[1], Fuller CC[2], Hawrusik R[2], Iyer GS [2], Koram N[3], Agan AA[2], Alam S[2], Avula R[4], Brown JS[5], Burk J[2], Connolly JG[2], Daniels K[4], DeFor T[6], DeVries A[7], Diessner BJ[8] Djibo DA[9], Ezzy SM[8], Cai B[3], Layton JB[1], Dea K[10], Tetreault-Langlois P[10], Lyons JG[2], Love SAM[4], Mayer SE[2], Ma Q[7], McMahill-Walraven CN[11], Nolan MB[6], Oyedele N[9], Peters A [2], Reynolds JS[2], Taggert E[8], Wideman K[1], Ziyadeh NJ[8], Gilsenan AW[1], Platt R[2] |
[1] RTI Health Solutions, USA, [2] Harvard Pilgrim Healthcare Institute, USA, [3] Pfizer, Inc., USA, [4] Carelon Research, USA, [5] TriNetX, LLC,USA, [6] HealthPartners Institute, USA, [7] Humana Healthcare Research, Inc., USA, [8] Optum, USA, [9] CVS Health, USA, [10] Statlog Inc., Canada, [11] Glade Oak Inc, USA |
|
Tuesday, September 1, 2026 |
3F-Three Panels on Safety & Effectiveness (mini session: Safety of COVID-19 Vaccines: the Final Answer) |
Associations of Pfizer-BioNTech COVID-19 Vaccine with Birth Outcomes: Results from a Post-approval Safety Study in the US |
Kawai AT[1], Bell E[2], Cosgrove A[2], Koram N[3], Avula R[4], Barret K[2], Cai B[3], Daniels K[4], Dea K[5], DeFor T[6], DeVries A[7], Diessner BJ[8], Djibo DA[9], Ezzy SM[8], Hawrusik R[2], Kempner ME[2], Layton JB[1], Love SAM[4], Ma Q[7], McMahill-Walraven CN[10], Messenger-Jones E[2], Michaelidis M[2], Nolan MB[6], Platt R[2], Shinde MU[2], Taggert E[8], Tetreault-Langlois P[5], Wang X[9], Wideman K[1], Ziyadeh NJ[8], Gilsenan AW[1], Fuller CC[2] |
[1] RTI Health Solutions, USA, [2] Harvard Pilgrim Healthcare Institute, USA, [3] Pfizer, Inc., USA, [4] Carelon Research, USA, [5] Statlog Inc., Canada, [6] HealthPartners Institute, USA, [7] Humana Healthcare Research, Inc., USA, [8] Optum, USA, [9] CVS Health, USA, [10] Glade Oak Inc, USA |
|
Tuesday, September 1, 2026 |
3A-Diabetes medications and safety outcomes |
A Post-authorization Safety Study on the Risk of In situ and Invasive Bladder Cancer in Real-World Use of Dapagliflozin in Patients with Type 2 Diabetes |
Gutierrez L[1], Danysh HE[2], Daniels K[3], Overbeek J[3], Aguado J[1], Bartsch J[2], Quimbo T[3], Baak BN[4], Garbinsky D[2], Calingaert B[2], Khan AM[2], Lemmens LA[4], Verburg I[4], Penning-van Beest F[4], Karlsson C[5], Chen H[6], Subramani B[7], Sjöström D[5], Aibibula W[8], Beachler DC[2], Gilsenan AW[1] |
[1] RTI Health Solutions, Spain, [2] RTI Health Solutions, USA, [3] Carelon Research, USA, [4] PHARMO Institute for Drug Outcomes Research, Netherlands, [5] AstraZeneca, Sweden, [6] AstraZeneca, USA, [7] AstraZeneca, India, [8] AstraZeneca, Canada |
|
Tuesday, September 1, 2026 |
3A-Diabetes medications and safety outcomes |
A Post-authorization Safety Study on the Risk of Invasive Breast Cancer in Real-World Use of Dapagliflozin in Patients with Type 2 Diabetes |
Gutierrez L[1], Danysh HE[2], Daniels K[3], Overbeek J[3], Aguado J[1], Bartsch J[2], Quimbo T[3], Baak BN[4], Garbinsky D[2], Calingaert B[2], Khan AM[2], Lemmens LA[4], Verburg I[4], Penning-van Beest F[4], Karlsson C[5], Chen H[6], Subramani B[7], Sjöström D[5], Aibibula W[8], Beachler DC[2], Gilsenan |
[1] RTI Health Solutions, Spain, [2] RTI Health Solutions, USA, [3] Carelon Research, USA, [4] PHARMO Institute for Drug Outcomes Research, Netherlands, [5] AstraZeneca, Sweden, [6] AstraZeneca, USA, [7] AstraZeneca, India, [8] AstraZeneca, Canada |
|
Wednesday, September 2, 2026 |
5A-Delivering Meaningful Answers in Clinical Decision-Making for Prenatal Exposures |
When to Start Follow-up in a Database Pregnancy Study? |
VanRompay MI[1], Wenziger C[1], Delahanty M[1], Schott K[1], Parlett LE[1], Lanes S[1] |
[1] Carelon Research, USA |
|
Poster presentations |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Monday, August 31, 2026 |
Poster Session A: Drug Utilization / Health Services Research / Health policy and governance |
[A-138] Impact of REMS Programs and Black Box Warnings on Laboratory Drug Safety Monitoring in Real-World Settings: A Schizophrenia Case Study |
Beachler DC[1], Onasanya O[1], Dudman D[1] |
[1] Carelon Research, USA |
|
Monday, August 31, 2026 |
Poster Session A: Geriatric Pharmacoepidemiology |
[A-194] Exploring Functional Quadriplegia Diagnoses: Documenting Increasing Incidence and Demographic Shifts in a U.S. Claims Database from 2008 to 2023 |
Hurwitz S[1], Yegneswaran B[2] |
[1] Carelon Research, USA, [2] Elevance Health, USA |
|
Monday, August 31, 2026 |
Poster Session A: Methods in Pharmacoepidemiology / Other |
[A-264] Representativeness of Linked Claims-EHR Data: Claims-only vs Claims+EHR Populations |
Parlett LE[1], Fournakis N[1], Ketkar A[1], Stephenson JJ[1], Beachler DC[1], Grabner M[1], Harris KM[1], Willey VJ[1] |
[1] Carelon Research, USA |
|
Monday, August 31, 2026 |
Poster Session A: Methods in Pharmacoepidemiology / Other |
[A-293] Designing and Conducting U.S. Multi Database Pharmacoepidemiologic Studies: Methodological Considerations and Lessons Learned |
Howell AV[1], Sinnott SJ[2], Breskin A[1], Gao S[1], Dodge L[3], Van Rompay MI[4], Wang F[3], Green J[1], Marcus A[1] |
[1] Regeneron Pharmaceuticals, Inc., USA, [2] Sanofi, USA, [3] Optum, USA, [4] Carelon Research, USA |
|
Monday, August 31, 2026 |
Poster Session A: Pregnancy and Lactation |
[A-327] Is disenrollment in pregnancy database studies ignorable? |
Delahanty M[1], Schott K[1], Crowe C[1], Lanes S[1], Kalloo G[1] |
[1] Carelon Research, USA |
|
Monday, August 31, 2026 |
Poster Session A: Pregnancy and Lactation |
[A-328] Ultrasound use during pregnancy in the Healthcare Integrated Research Database (HIRD), 2024-2025 |
Delahanty M[1], Crowe C[1], Kalloo G[1], Lanes S[1] |
[1] Carelon Research, USA |
|
Monday, August 31, 2026 |
Poster Session A: Safety Outcomes / Cancer |
[A-405] Impact of Package Insert Warning on Liver Function Tests for CDK4/6 inhibitors for HR+/HER2-Breast Cancer |
Beachler, DC[1], Lo Re III V[2], Lanes S[1] |
[1] Carelon Research, USA, [2] Rutgers University, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Disease Epidemiology / Clinical Course / Cancer |
[B-003] Comparative risk factors among pancreatic adenocarcinoma patients vs. neuroendocrine vs. other pancreatic cancer patients |
Beachler DC[1], Parlett, L[1], Petrick JL[2], Debono D[3], Barron J[1], Lanes S[1], Fisch M[3] |
[1] Carelon Research, USA, [2] Boston University, USA [3] Carelon Specialty Care Services, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Drug Utilization / Health Services Research / Other |
[B-131] How Representative Are Licensable Datasets Compared To Their Source Population |
Parlett LE[1], Kalloo G[1], Ketkar A[1], Stephenson JJ[1], Beachler DC[1], Grabner M[1], Harris KM[1], Willey VJ[1] |
[1] Carelon Research, USA |
|
Tuesday, September 1, 2026 |
Poster session B: pregnancy and lactation |
[B-138] Association Between Recency of Requested Medical Records and Medical Record Obtainment in Claims-based Algorithm Validation Studies |
Quimbo T[1], Paullin M[1], Marshall A[1], Beachler DC[1], Onasanya O[1] |
[1] Carelon Research, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Drug Utilization / Health Services Research / Other |
[B-145] A Cross-Sectional Patient Survey Study to Inform Ascertainment of Rimegepant Indication in Administrative Healthcare Claims: Acute or Preventive Migraine Treatment? |
McDonald SC[1], Seals RM[2], Bell EJ[3], Delahanty M[4], Franklin J[2], Hardy JR[5], Lanes S[4], Margulis AV[6], Parlett LE[4], Rivero-Ferrer E[6], Seeger JD[2], Asomaning K[7] |
[1] Pfizer, Inc., Canada, [2] Optum, USA, [3] Harvard Pilgrim Health Care Institute, USA, [4] Carelon Research, USA, [5] Biohaven Pharmaceuticals, Canada, [6] RTI Health Solutions, Spain, [7] Pfizer, Inc., USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Drug Utilization / Health Services Research / Other |
[B-146] Assessing Patient Use Metrics for Migraine Medication Taken Daily or As Needed: A Cross-Sectional Survey |
McDonald SC[1], Seals RM[2], Bell EJ [3], Delahanty M[4], Franklin J[2], Hardy JR[5], Lanes S[4], Margulis AV[6], Parlett LE[4], Rivero-Ferrer E[6], Seeger JD[2], Asomaning K[7] |
[1] Pfizer, Inc., Canada, [2] Optum, USA, [3] Harvard Pilgrim Health Care Institute, USA, [4] Carelon Research, USA, [5] Biohaven Pharmaceuticals, Canada, [6] RTI Health Solutions, Spain, [7] Pfizer, Inc., USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Drug Utilization / Health Services Research / Quality use of medicines (including indicators and guidelines) |
[B-177] Discordant Drug Label Warning Severity Over Time and Impact on the Uptake of DPYD Gene Testing Among New Users of Capecitabine and 5-Fluorouracil in Real World US Healthcare Settings |
Dudman D[1], Beachler DC[1], Onasanya O[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Methods in Pharmacoepidemiology / Measurement Methods |
[B-211] Validation of algorithms for breast cancer and bladder cancer among new users of antidiabetics in real world data |
Daniels K[1], Danysh H[2], Gutierrez L[3], Kaye JA[2], Garcia-Albeniz X[3], Schmid R[4], Gilsenan AW[2], Quimbo T [1], Beachler DC[1] |
[1] Carelon Research, USA, [2] RTI Health Solutions, USA, [3] RTI Health Solutions, Spain, [4] The South Bend Clinic, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Methods in Pharmacoepidemiology / Measurement Methods |
[B-228) Lessons Learned from Conducting Validation Studies in the Healthcare Integrated Research Database |
Martinez K[1], Wong K[1], Love SAM[1], Daniels K[1], Paullin M[1] |
[1] Carelon Research, USA |
|
Tuesday, September 1, 2026 |
Posters Session B: Vaccines |
[B-413] Incidence Rates of Guillain-Barré Syndrome in Adult Populations in the United States: A Healthcare Database Study to Inform Vaccine Safety Studies |
Bell EJ[1], Sun J]2], Horgan C[1], Back S[1], Emerton D[1], Round K[1], Walsh S[1], Cole D[1], Rajbhandari R[1], Vasquez A[1], Xu S[3], Contreras R[3], Hsu C[3], Ma Q[4], DeVries A[4], Oyedele N[5], Djibo DA[5] Wentz A[6], Love SAM[6], Wu J[2], Kelly S[2], Maro JC[1], Platt R[1], Cocoros NM[1] |
[1] Harvard Pilgrim Health Care Institute, USA, [2] Pfizer, Inc., USA, [3] Southern California Permanente Medical Group, USA, [4] Humana Healthcare Research, Inc., USA, [5] CVS Health, USA, [6] Carelon Research, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Vaccines |
[B-422] Validation of a Claims-Based Algorithm for Myocarditis/Pericarditis and Assessment of the Impact of Outcome Misclassification in a US Postapproval Study of COVID-19 Vaccine Safety |
Fuller CC[1], Kawai AT[2], Daniels K[3], Iyer GS [4], Koram N[5], Avula R[3], Brown JS[6], Cai B[5], Clasen SC[7] Hawrusik R[4], Layton JB [2], Love SAM[3], Martinez K[3], Messenger-Jones E[4], Paullin M[3], Rabbani R[8], Reynolds S[4] Wideman[2], Uribe W[9] Platt R[10], Gilsenan AW[2] |
[1] Harvard Pilgrim Health Care Institute and Harvard Medical School, USA, [2] RTI Health Solutions, USA, [3] Carelon Research, USA, [4] Harvard Pilgrim Health Care Institute, USA, [5] Pfizer, Inc., USA, [6] TriNetX, LLC, USA, [7] Indiana University Health, USA, [8] Jackson Memorial Hospital, USA, [9] CES University, Colombia, [10] Harvard Medical School, USA |
|
Tuesday, September 1, 2026 |
Poster Session B: Vaccines |
[B-435] Enhancing Vaccine Exposure Ascertainment for Post-Authorization Safety Surveillance Using Linked Immunization Information System and Administrative Claims Data |
Love SAM[1], Parlett LE[1], Wong K[1], Avula R[1], Chaudhary SM[1], Secora A[2], Faughnan K[2], Goodman M[2], Darkoh N[2], Weed R[2], Williams N[2], Lo A[3], Acharya G[3], Ni S[3], Chillarige Y[3], Beachler DC[1] |
[1] Carelon Research, USA, [2] IQVIA, USA, [3] Acumen, LLC, USA |
|
Wednesday, September 2, 2026 |
Poster Session C: Biologics / Biosimilars |
[C-032] Use of medical records to assess free medication samples missing in claims |
Hurwitz SR[1], Daniels K[1], Torre M[1], Coley B[1], Lanes S[1] |
[1] Carelon Research, USA |
|
Wednesday, September 2, 2026 |
Poster Session C: Health Economics / Outcomes Research |
[C-281] Assessing the Representativeness of Survey-Eligible Individuals Identified from a Large US National Claims Database |
Stephenson JJ[1], Wilson RC[1], Parlett LE[1], Ketkar A[1], Beachler DC[1], Grabner M[1], Harris KM[1], Willey VJ[1] |
[1] Carelon Research, USA |
|
Wednesday, September 2, 2026 |
Poster Session C: Health Equity |
[C-301] Rurality, socioeconomic status, and healthcare utilization: An analysis of claims data integrated with social drivers of health |
Johnson M[1], Avula R[1], Sponholtz T[1], Price A[1], Silver C[1], Grabner M[1], Stephenson JJ[1] |
[1] Carelon Research, USA |
|
Wednesday, September 2, 2026 |
Poster Session C: Methods in Pharmacoepidemiology / Analytical Methods |
[C-348] Potential bias in database studies restricted to adjudicated true cases |
Sponholtz T [1], Wenziger C[1], Beachler DC[1], Lanes S[1] |
[1] Carelon Research, USA |
|
Wednesday, September 2, 2026 |
Poster Session C: Pharmacovigilance/Cancer |
[C-353] Incidence of composite cancer outcomes among dapagliflozin initiators compared to other glucose lowering drugs in the US and Europe |
Daniels K[1], Gutierrez L[2], Danysh H [3], Quimbo T[1], Overbeek J[4], Gilsenan A[3], Aguado J [2], Baak BN[4], Verburg I[4], Lemmens LA[4], Penning-van Beest F[4], Bartsch J[3], Garbinsky D[3], Calingaert B[3], Khan AM[3], Karlsson C[6], Sjöström D[6], Subramani B[7], Chen H[8], Aibibula W[9], Beachler DC[1] |
[1] Carelon Research, USA, [2] RTI Health Solutions, Spain, [3] RTI Health Solutions, USA, [4] PHARMO Institute for Drug Outcomes Research, Netherlands, [5] RTI Health Solutions, Spain, [6] AstraZeneca, Sweden, [7] AstraZeneca, India, [8] AstraZeneca, USA, [9] AstraZeneca, Canada
|